Aurobindo Pharma acquires A1 Biochem Labs for $15.2 million
pre-market1 source ↓written by the desknot a recommendation
- Labs LLC
- $15.247 million
- in 2025
- $5.92 million
- in 2024
- $9.23 million
Aurobindo Pharma's subsidiary, Apitoria, has completed the acquisition of A1 Biochem Labs LLC for $15.247 million. This all-cash deal enhances Aurobindo's capabilities as a Contract Research, Development, and Manufacturing Organization (CRDMO), expanding its research presence in the US.
• A1 Biochem Labs reported a turnover of $5.92 million in 2025 and $9.23 million in 2024.
This strategic move is expected to bolster Aurobindo's global R&D ecosystem significantly.
Not investment advice. For informational purposes only.